Valuation: Avacta Group Plc

Market Cap 337M 445M 396M 370M 633M 42.87B 643M 4.47B 1.72B 21.85B 1.67B 1.64B 70.39B P/E 2026 *
-11.2x
P/E 2027 * -13x
Enterprise Value 334M 441M 392M 366M 627M 42.42B 636M 4.42B 1.7B 21.62B 1.65B 1.62B 69.65B EV / Sales 2026 *
121x
EV / Sales 2027 * 43.7x
Free-Float
97.08%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: Avacta Group Plc

1 week-2.70%
1 month+5.88%
3 months-2.17%
6 months+12.50%
Current year+24.14%
1 week 70.72
Extreme 70.725
77
1 month 64
Extreme 64
88
Current year 48
Extreme 48
92
1 year 48
Extreme 48
92
3 years 26
Extreme 26
166.98
5 years 26
Extreme 26
187.98
10 years 13
Extreme 13
291.8
Manager TitleAgeSince
Chief Executive Officer 56 01/04/2024
Director of Finance/CFO 51 22/01/2025
Chief Tech/Sci/R&D Officer - 09/02/2026
Director TitleAgeSince
Director/Board Member 71 17/08/2021
Director/Board Member 56 18/03/2022
Director/Board Member 59 28/05/2025
Date Insider Type Main position Quantity % Market Cap. Importance
02/09/24 Sell

Chief Financial Officer

500,000 0.1393%
02/09/24 Free

Chief Executive Officer

3,600,000 1.0027%
02/09/24 Exercice

Chief Financial Officer

500,000 0.1393%
Change 5-day change 1-year change 3-year change Capi.($)
-.--%-2.70%+17.07%-39.50% 448M
+4.16%-0.36%+49.37%+94.17% 74.46B
-0.61%+0.69%+36.36%+82.72% 60.14B
-2.54%-0.21%+6.34%+31.72% 48.15B
-3.02%-2.67%+37.26%+32.51% 44.25B
+0.31%+7.94%+340.88%+643.82% 43.99B
-1.96%-1.71%+5.30%+99.46% 41.61B
+3.32%+3.49%+11.18%+51.23% 29.97B
+4.77%+6.16%+36.77%+22.78% 29.31B
-4.86%-8.24%-24.60%+330.06% 24.93B
Average -0.04%+1.37%+51.59%+134.90% 39.73B
Weighted average by Cap. +0.17%+1.82%+60.02%+145.57%

Financials

2026 *2027 *
Net sales 2.75M 3.63M 3.23M 3.02M 5.16M 349M 5.24M 36.44M 14.01M 178M 13.61M 13.33M 574M 8.1M 10.69M 9.5M 8.88M 15.2M 1.03B 15.43M 107M 41.26M 524M 40.09M 39.25M 1.69B
Net income -28.92M -38.15M -33.92M -31.71M -54.26M -3.67B -55.07M -383M -147M -1.87B -143M -140M -6.03B -23.64M -31.18M -27.73M -25.92M -44.35M -3B -45.02M -313M -120M -1.53B -117M -115M -4.93B
Net Debt -3.52M -4.64M -4.13M -3.86M -6.6M -447M -6.7M -46.62M -17.92M -228M -17.41M -17.05M -734M 16.14M 21.3M 18.94M 17.7M 30.29M 2.05B 30.75M 214M 82.23M 1.05B 79.9M 78.23M 3.37B
Logo Avacta Group Plc
Avacta Group plc is a United Kingdom-based life sciences company developing peptide drug conjugates (PDC) targeting anti-tumor payloads directly to the tumor. The Company is focused on the development of its proprietary preCISION technology platform. The preCISION platform is a highly specific substrate for fibroblast activation protein (FAP) which is upregulated in most solid tumors compared with healthy tissues. The preCISION platform harnesses this tumor-specific protease to cleave preCISION peptide drug conjugates and preCISION antibody/Affimer drug conjugates in the tumor microenvironment, thus releasing active payload in the tumor and reducing systemic exposure and toxicity. Its lead program, AVA6000, is a clinical-stage asset which is a preCISION-enabled form of doxorubicin. AVA6103, the Company’s second program, is a preCISION-enabled PDC comprised of the preCISION peptide linked to exatecan, the most potent topoisomerase I (topo I) inhibitor in clinical development.
Employees
81
Date Price Change Volume
29/09/26 GBX 72.00 -0.69% 614,155
28/09/26 GBX 72.50 -0.41% 532,003
25/09/26 GBX 72.80 -1.62% 1,880,265
24/09/26 GBX 74.00 -1.33% 358,934
23/09/26 GBX 75.00 -.--% 748,154
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
B
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
0.7200GBP
Average target price
0.9425GBP
Spread / Average Target
+30.90%

Annual profits - Rate of surprise

  1. Stock Market
  2. Stocks
  3. AVCT Stock